Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)

Next Previous
Search
Trial Profile

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Simtuzumab (Primary)
  • Indications Hepatic fibrosis; Primary sclerosing cholangitis
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences

Most Recent Events

  • 08 Nov 2022 Results assessing the diagnostic utility of NITs for identifying significant fibrosis (Ludwig F2-F4), advanced fibrosis (F3-F4) and cirrhosis (F4) and liver stiffness measurement with fibrosis stages in patients with primary sclerosing cholangitis, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
  • 26 Jun 2022 Results assessing associations between these biomarkers with fibrosis stage and PSC-related clinical events in a longitudinal study, presented at The International Liver Congress 2022.
  • 26 Jun 2021 Results assessing deep learning approach to analysis of MRCP images predicts clinical events and progression to cirrhosis in patients with primary sclerosing cholangitis presented at The International Liver Congress 2021

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top